Business Context and Reporting Period
This Form 8-K is a current report filed by Histogenics Corporation (not Ocugen, Inc.) on July 14, 2015, regarding events occurring on July 14 and July 15, 2015. The filing announces the appointment of a new executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Base Salary: $330,000 annually for the new Chief Medical Officer.
- Target Bonus: 35% of the annual base salary.
- Equity Grant (Initial Option): 120,000 shares of Common Stock, vesting over four years (25% after the first year).
- Equity Grant (Performance Grant): 30,000 shares, contingent on the stock price reaching or exceeding $19.92 for 60 consecutive days within four years.
Material Changes
The material change reported is the hiring of Gloria Matthews, DVM, Ph.D., DACVS, as the Company's Chief Medical Officer. Dr. Matthews joins from Genzyme (a Sanofi company), where she served as Senior Scientific Director and Global Head of Bone & Joint R&D.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the hire and the terms of the employment agreement. The filing notes that the Initial Option and Performance Grant are subject to approval by the Board of Directors or the Compensation Committee. No specific risks, contingencies, or forward-looking guidance regarding financial performance are included in this report.
Investor Verification Checklist
- Verify the Board of Directors' approval of the 120,000 share Initial Option and the 30,000 share Performance Grant.
- Confirm the vesting schedule and exercise price for the Performance Grant once granted.
- Review the press release (Exhibit 99.1) for additional details on Dr. Matthews' strategic role.
- Note that the filing references "Histogenics Corporation," not "Ocugen, Inc." as indicated in the request metadata.